Cure My Disease

Don't miss your cure!

 Log in / Sign up

HIV drug combo may shield hearts: new trial launches

NCT ID NCT07030920

Recruiting now Disease control Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug fostemsavir to standard HIV treatment can lower the risk of heart disease in people with well-controlled HIV. Researchers will compare heart imaging and blood tests between 150 adults who get the extra drug and those who don't. Participants must be 40 or older (or have had HIV for 25+ years) and have at least one heart risk factor like smoking or high blood pressure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR RISK FACTOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR RISK FACTOR HUMAN IMMUNODEFICIENCY VIRUS (HIV)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • CR CHUM

    RECRUITING

    Montreal, Quebec, H2X 0A9, Canada

    Contact

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••